Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
Sponsor: Novartis Pharmaceuticals
Summary
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
Official title: Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
117
Start Date
2023-04-03
Completion Date
2023-09-29
Last Updated
2026-06-17
Healthy Volunteers
No
Locations (7)
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Rostock, Germany
Novartis Investigative Site
Stuttgart, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Würzburg, Germany